Compare RICK & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RICK | SGMT |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.0M | 169.4M |
| IPO Year | 1996 | 2021 |
| Metric | RICK | SGMT |
|---|---|---|
| Price | $24.72 | $5.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $98.00 | $26.38 |
| AVG Volume (30 Days) | 77.5K | ★ 358.0K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ 272.73 | N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $144,896,000.00 | $2,000,000.00 |
| Revenue This Year | $19.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.76 | $2.02 |
| 52 Week High | $43.21 | $11.41 |
| Indicator | RICK | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 54.76 |
| Support Level | $23.71 | $4.97 |
| Resistance Level | $25.07 | $6.08 |
| Average True Range (ATR) | 1.17 | 0.35 |
| MACD | 0.19 | 0.08 |
| Stochastic Oscillator | 84.82 | 80.70 |
RCI Hospitality Holdings Inc through its subsidiaries owns and operates establishments that offer live adult entertainment, restaurant, and or bar operations. It also owns and operates a communication company serving the adult nightclub industry. The company's operating business segments are Nightclubs, Bombshells, and Others. It operates nightclubs through the following brands Rick's Cabaret, Vivid Cabaret, Tootsie's Cabaret, Club Onyx, and Jaguars Club. In the Bombshells segment, the company is building a chain of Restaurants and Sports Bars in Dallas, Austin, and Houston, Texas. It derives the majority of revenue from the Nightclubs segment that engages in the sale of alcoholic beverages, food, and merchandise items; service in the form of cover charges, dance fees, and room rentals.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.